$TEM · Tempus AI, Inc.
Tempus AI filed Amendment No. 1 to its S-4 registration statement on October 2, 2026, for the proposed acquisition of Personalis, Inc. The deal, originally announced July 20, 2026, uses a two-step merger structure where Personalis shareholders receive Tempus Class A common stock at an exchange ratio of 0.3356 if Tempus trades at or below $48.42, or $16.25 worth of Tempus shares if above that floor. Tempus retains the right to elect to pay cash for up to 50% of Personalis shares at $16.25 per share.
- Tempus will acquire Personalis via a two-step merger structure using Merger Sub I and Merger Sub II.
- Each Personalis share converts to 0.3356 Tempus shares if Tempus stock price ≤ $48.42, or $16.25 worth of Tempus shares if above.
- Tempus may elect to pay cash for up to 50% of Personalis shares at $16.25 per share.
- Merck entered a Voting Agreement to vote its Personalis shares in favor of the deal.
- No Tempus stockholder vote is required; only Personalis stockholders must approve the merger.
TEM shares are essentially flat in extended hours (+0.09% vs price-at-filing), suggesting the amended S-4 contained no material surprises relative to the original July 20, 2026 merger announcement.
The amended S-4 advances a strategic consolidation in AI-powered genomics, with the variable exchange ratio and Tempus cash election creating meaningful deal-close uncertainty for arbitrageurs.
This is a consolidation play in AI-driven precision medicine — Tempus (diagnostics/data) absorbing Personalis (genomic sequencing). The structure with Merck as a supportive voter signals pharma alignment behind the combination.
The exchange ratio is variable: if Tempus stock trades above $48.42, Personalis holders receive fewer shares (fixed at $16.25 value), creating uncertainty about final consideration. Tempus's cash election right could reduce equity consideration for up to 50% of Personalis shares. The deal requires a
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.